or Try an Advanced Search...

    Treatment Of Breast Cancer Stocks List

    Symbol Grade Name % Change
    SNDX F Syndax Pharmaceuticals, Inc. -0.69
    GLSI F Greenwich LifeSciences, Inc. -0.70
    NKTR F Nektar Therapeutics 0.50
    PDSB F PDS Biotechnology Corporation 4.94
    CRIS F Curis, Inc. 9.73
    SLRX F Salarius Pharmaceuticals, Inc. 5.71
    BCTX F BriaCell Therapeutics Corp. 24.60
    BPTH F Bio-Path Holdings Inc 2.83
    TCON F TRACON Pharmaceuticals, Inc. -31.40
    OLMA F Olema Pharmaceuticals, Inc. -1.57
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Medical Instruments & Supplies Software - Application
    Related Stock Lists: Breast Cancer Cancer Biopharmaceutical Medicine Biotechnology Clinical Medicine Her2 Her2/Neu Ovarian Cancer Advanced Breast Cancer Advanced Cancer Antiestrogens Breast Imaging Cancer Research Cancer Screening Cancer Treatment Drugs Endometrial Cancer Epidermal Growth Factor Receptor Estrogen

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Breast Cancer stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 2.59
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 1.62
    SURI C Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 1.47
    SBIO C ALPS Medical Breakthroughs ETF 1.47
    XBI D SPDR S&P Biotech ETF 0.57
    View all Treatment Of Breast Cancer ETFs...
    Compare ETFs
    Compare BBC to SURI Compare BBC to XBI Compare CNCR to BBC

        Treatment Of Breast Cancer Stocks Recent News

        Date Stock Title
        Nov 21 BCTX BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study
        Nov 20 PDSB Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
        Nov 18 NKTR Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
        Nov 18 SNDX Syndax secures FDA OK for new kind of leukemia drug
        Nov 18 SNDX FDA approves Syndax’s Revuforj to treat leukaemia
        Nov 15 SNDX Syndax wins FDA approval for leukemia drug revumenib
        Nov 15 SNDX Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
        Nov 15 BPTH Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript
        Nov 15 BPTH Bio-Path: Q3 Earnings Snapshot
        Nov 15 BPTH Bio-Path GAAP EPS of -$0.70
        Nov 15 BPTH Bio-Path Holdings Reports Third Quarter 2024 Financial Results
        Nov 15 BPTH Earnings Scheduled For November 15, 2024
        Nov 15 PDSB PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
        Nov 15 SLRX Salarius: Q3 Earnings Snapshot
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Medical Instruments & Supplies Software - Application
        Related Stock Lists: Breast Cancer Cancer Medicine Biopharmaceutical Clinical Medicine Oncology Epidermal Growth Factor Receptor Her2 Her2/Neu Ovarian Cancer Prostate Cancer Solid Tumors Advanced Cancer Antiestrogens Antineoplastic Drugs Biotechnology Clinical Development Drugs Estrogen Estrogen Receptor
        Treatment Of Breast Cancer

        Treatment of breast cancer depends on the type and stage of the cancer, as well as the patient's age, overall health, and personal preferences. Treatment options may include surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and/or immunotherapy.

        Browse All Tags